About
Gene Therapy, Gene editing platform, delivery vector platform
Areas of Focus
Categories
Non-PharmaceuticalVirus TechnologyGene Therapy, RNA & Peptide TherapyDrug Delivery & FormulationChina
Clinical Trials (8)
View allTotal Trials
8
As Lead Sponsor
7
As Collaborator
1
Total Enrollment
74
By Phase
EARLY_PHASE1: 4PHASE1: 1NA: 2PHASE1/PHASE2: 1
By Status
RECRUITING: 5NOT_YET_RECRUITING: 1WITHDRAWN: 1ACTIVE_NOT_RECRUITING: 1
Clinical Trials Pipeline8 trials
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
2022
2023
2024
2025
2026
2027
2028
2029
2030
2031
2032
Today
Hover over trial bars to see details
Recent Trials
NCT07063251Lead Sponsor
An Clinical Study Evaluating the Safety, Tolerability, and efficAcy of HG005 in StaRgardT Disease
EARLY_PHASE1Recruiting
6 participants
Started: Aug 20, 2025 · Completed: Feb 28, 2028
NCT06623279Lead Sponsor
Open-laBel Dose-escalation Study for CRISPR/cas13- Rna TargetInG THerapy for the Treatment of Neovascular Age-related Macular Degeneration in Phase I Trial
PHASE1Not yet recruiting
15 participants
Started: Apr 1, 2025 · Completed: Feb 1, 2031
NCT06594094Lead Sponsor
An Open-label, Multidose Dose-escalation Study to Understand the Safety of CRISPR Gene-editing Therapy and Its Long-Lasting Effects in DMD Patients (MUSCLE)
NARecruiting
6 participants
Started: Nov 6, 2024 · Completed: Sep 30, 2026
NCT06615206Lead Sponsor
A First-in-Human Clinical Trial to Evaluate the Safety, Tolerability, and Efficacy of a Novel CRISPR RNA-editing Therapy in Patients with Mecp2 Duplication Syndrome, a Rare Orphan Disease (HERO)
NARecruiting
6 participants
Started: Oct 30, 2024 · Completed: Oct 31, 2026
NCT05906953Lead Sponsor
Safety and Efficacy Trial of HG004 for Leber Congenital Amaurosis Related to Rpe65 Gene Mutations (STAR)
PHASE1/PHASE2Recruiting
20 participants
Started: Oct 31, 2023 · Completed: Dec 31, 2025
Locations (1)
Headquarters
Shanghai, China
Map
Loading map...